Tune Therapeutics' 2025 Epigenome Editing Outlook

A conversation with Derek Jantz, CSO, Tune Therapeutics

Progress in modifying gene expression last year set an optimistic stage for more milestones in 2025.

In an interview, Derek Jantz, chief scientific officer at Tune Therapeutics, talks about key innovations in gene therapy in 2024. He emphasizes epigenome editing as a major advancement, allowing for precise control of gene expression without altering DNA sequences, unlike gene editing.

He highlights the development of single-cell multi-omics assays, which provide detailed information about cell populations on a cell-by-cell basis. Additionally, he points to LNP mRNA technology as crucial, noting its increased use and the potential for mRNA therapies to become more economically viable.

Jantz says he’s skeptical about LNP’s ability to target tissues beyond the liver, but he remains hopeful about new approaches in that area. He also touches on the potential effects a new administration could have on regulatory processes but, acknowledging the uncertainty, suggests an observant wait-and-see approach is more appropriate.